KSH01-TCRT Solid Tumors
Recruiting now · Early Phase 1
Conditions studied: TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
In brief
1\) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
Key facts
- Study ID
- NCT05539833
- Run by
- TCRx Therapeutics Co.Ltd
- People needed
- 50
- Starts
- 2022-08-19
- Expected to finish
- 2027-07-31
- Last updated by the study team
- 2023-04-03
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The first affiliated hospital of Guang Xi medical university — Nanning, Guangxi, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.